Impact of induction immunosuppression on survival in heart transplant recipients

A contemporary analysis of agents

Bryan A. Whitson, Ahmet Kilic, Amy Lehman, Allison Wehr, Ayesha Hasan, Garrie Haas, Don Hayes, Chittoor Sai Sudhakar, Robert S.D. Higgins

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: The impact of induction immunosuppression on long-term survival in heart transplant recipients is unclear. Over the past three decades, practices have varied as induction agents have changed and experiences grew. We sought to evaluate the effect of contemporary induction immunosuppression agents in heart transplant recipients with the primary endpoint of survival, utilizing national registry data. Methods: We queried the United Network for Organ Sharing (UNOS) data registry for all heart transplants from 1987 to 2012. We restricted our analysis to adult (≥18 yr) recipients performed from 2001-2011 (to allow for the potential for a minimum of 12 months post-transplant follow-up) who received either: no antibody based induction (NONE) or the contemporary agents (INDUCED) of either: basiliximab/daclizumab (IL-2Rab), alemtuzumab, or ATG/ALG/thymoglobulin. Kaplan-Meier estimates of the survival function as well as Cox proportional hazards models were utilized. Results: Of the 17 857 heart transplants that met the inclusion criteria, there were 4635 (26%) reported deaths during the follow-up period. There were 8216 (46%) patients who were INDUCED. Of the INDUCED agents, 55% were IL-2Rab, 4% alemtuzumab, and 40% ALG/ATG/thymoglobulin. Donor and recipient characteristics were evaluated. Overall, being INDUCED did not significantly affect survival in univariable (p = 0.522) and multivariable (p = 0.130) Cox models as well as a propensity score adjusted model (p = 0.733). Among those induced, ATG/ALG/thymoglobulin appeared to have superior survival as compared with IL-2Rab (log-rank p = 0.007, univariable hazard ratio [HR] = 0.886; 95% CI: 0.811-0.968; p = 0.522). However, in a multivariable Cox model that adjusted for recipient age, VAD, BMI, steroid use, CMV match, and ischemic time, the hazard ratio for ALG/ATG/thymoglobulin vs. IL-2Rab was no longer statistically significant (HR = 0.948; 95% CI: 0.850-1.058; p = 0.341). Conclusion: In a contemporary analysis of heart transplant recipients, an overall analysis of induction agents does not appear to impact survival, as compared to no induction immunosuppression. While ALG/ATG/thymoglobulin appeared to have a beneficial effect on survival compared to IL-2Rab in the univariable model, this difference was no longer statistically significant once we adjusted for clinically relevant covariates.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalClinical Transplantation
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Immunosuppression
Survival
Proportional Hazards Models
Transplants
Registries
Propensity Score
Information Dissemination
Kaplan-Meier Estimate
Transplant Recipients
Interleukin-4
Steroids
thymoglobulin
Tissue Donors
Antibodies

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Whitson, B. A., Kilic, A., Lehman, A., Wehr, A., Hasan, A., Haas, G., ... Higgins, R. S. D. (2015). Impact of induction immunosuppression on survival in heart transplant recipients: A contemporary analysis of agents. Clinical Transplantation, 29(1), 9-17. https://doi.org/10.1111/ctr.12469

Impact of induction immunosuppression on survival in heart transplant recipients : A contemporary analysis of agents. / Whitson, Bryan A.; Kilic, Ahmet; Lehman, Amy; Wehr, Allison; Hasan, Ayesha; Haas, Garrie; Hayes, Don; Sai Sudhakar, Chittoor; Higgins, Robert S.D.

In: Clinical Transplantation, Vol. 29, No. 1, 01.01.2015, p. 9-17.

Research output: Contribution to journalArticle

Whitson, Bryan A. ; Kilic, Ahmet ; Lehman, Amy ; Wehr, Allison ; Hasan, Ayesha ; Haas, Garrie ; Hayes, Don ; Sai Sudhakar, Chittoor ; Higgins, Robert S.D. / Impact of induction immunosuppression on survival in heart transplant recipients : A contemporary analysis of agents. In: Clinical Transplantation. 2015 ; Vol. 29, No. 1. pp. 9-17.
@article{b0d943aa207a4c68be18a21faaa51c09,
title = "Impact of induction immunosuppression on survival in heart transplant recipients: A contemporary analysis of agents",
abstract = "Introduction: The impact of induction immunosuppression on long-term survival in heart transplant recipients is unclear. Over the past three decades, practices have varied as induction agents have changed and experiences grew. We sought to evaluate the effect of contemporary induction immunosuppression agents in heart transplant recipients with the primary endpoint of survival, utilizing national registry data. Methods: We queried the United Network for Organ Sharing (UNOS) data registry for all heart transplants from 1987 to 2012. We restricted our analysis to adult (≥18 yr) recipients performed from 2001-2011 (to allow for the potential for a minimum of 12 months post-transplant follow-up) who received either: no antibody based induction (NONE) or the contemporary agents (INDUCED) of either: basiliximab/daclizumab (IL-2Rab), alemtuzumab, or ATG/ALG/thymoglobulin. Kaplan-Meier estimates of the survival function as well as Cox proportional hazards models were utilized. Results: Of the 17 857 heart transplants that met the inclusion criteria, there were 4635 (26{\%}) reported deaths during the follow-up period. There were 8216 (46{\%}) patients who were INDUCED. Of the INDUCED agents, 55{\%} were IL-2Rab, 4{\%} alemtuzumab, and 40{\%} ALG/ATG/thymoglobulin. Donor and recipient characteristics were evaluated. Overall, being INDUCED did not significantly affect survival in univariable (p = 0.522) and multivariable (p = 0.130) Cox models as well as a propensity score adjusted model (p = 0.733). Among those induced, ATG/ALG/thymoglobulin appeared to have superior survival as compared with IL-2Rab (log-rank p = 0.007, univariable hazard ratio [HR] = 0.886; 95{\%} CI: 0.811-0.968; p = 0.522). However, in a multivariable Cox model that adjusted for recipient age, VAD, BMI, steroid use, CMV match, and ischemic time, the hazard ratio for ALG/ATG/thymoglobulin vs. IL-2Rab was no longer statistically significant (HR = 0.948; 95{\%} CI: 0.850-1.058; p = 0.341). Conclusion: In a contemporary analysis of heart transplant recipients, an overall analysis of induction agents does not appear to impact survival, as compared to no induction immunosuppression. While ALG/ATG/thymoglobulin appeared to have a beneficial effect on survival compared to IL-2Rab in the univariable model, this difference was no longer statistically significant once we adjusted for clinically relevant covariates.",
author = "Whitson, {Bryan A.} and Ahmet Kilic and Amy Lehman and Allison Wehr and Ayesha Hasan and Garrie Haas and Don Hayes and {Sai Sudhakar}, Chittoor and Higgins, {Robert S.D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/ctr.12469",
language = "English (US)",
volume = "29",
pages = "9--17",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Impact of induction immunosuppression on survival in heart transplant recipients

T2 - A contemporary analysis of agents

AU - Whitson, Bryan A.

AU - Kilic, Ahmet

AU - Lehman, Amy

AU - Wehr, Allison

AU - Hasan, Ayesha

AU - Haas, Garrie

AU - Hayes, Don

AU - Sai Sudhakar, Chittoor

AU - Higgins, Robert S.D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: The impact of induction immunosuppression on long-term survival in heart transplant recipients is unclear. Over the past three decades, practices have varied as induction agents have changed and experiences grew. We sought to evaluate the effect of contemporary induction immunosuppression agents in heart transplant recipients with the primary endpoint of survival, utilizing national registry data. Methods: We queried the United Network for Organ Sharing (UNOS) data registry for all heart transplants from 1987 to 2012. We restricted our analysis to adult (≥18 yr) recipients performed from 2001-2011 (to allow for the potential for a minimum of 12 months post-transplant follow-up) who received either: no antibody based induction (NONE) or the contemporary agents (INDUCED) of either: basiliximab/daclizumab (IL-2Rab), alemtuzumab, or ATG/ALG/thymoglobulin. Kaplan-Meier estimates of the survival function as well as Cox proportional hazards models were utilized. Results: Of the 17 857 heart transplants that met the inclusion criteria, there were 4635 (26%) reported deaths during the follow-up period. There were 8216 (46%) patients who were INDUCED. Of the INDUCED agents, 55% were IL-2Rab, 4% alemtuzumab, and 40% ALG/ATG/thymoglobulin. Donor and recipient characteristics were evaluated. Overall, being INDUCED did not significantly affect survival in univariable (p = 0.522) and multivariable (p = 0.130) Cox models as well as a propensity score adjusted model (p = 0.733). Among those induced, ATG/ALG/thymoglobulin appeared to have superior survival as compared with IL-2Rab (log-rank p = 0.007, univariable hazard ratio [HR] = 0.886; 95% CI: 0.811-0.968; p = 0.522). However, in a multivariable Cox model that adjusted for recipient age, VAD, BMI, steroid use, CMV match, and ischemic time, the hazard ratio for ALG/ATG/thymoglobulin vs. IL-2Rab was no longer statistically significant (HR = 0.948; 95% CI: 0.850-1.058; p = 0.341). Conclusion: In a contemporary analysis of heart transplant recipients, an overall analysis of induction agents does not appear to impact survival, as compared to no induction immunosuppression. While ALG/ATG/thymoglobulin appeared to have a beneficial effect on survival compared to IL-2Rab in the univariable model, this difference was no longer statistically significant once we adjusted for clinically relevant covariates.

AB - Introduction: The impact of induction immunosuppression on long-term survival in heart transplant recipients is unclear. Over the past three decades, practices have varied as induction agents have changed and experiences grew. We sought to evaluate the effect of contemporary induction immunosuppression agents in heart transplant recipients with the primary endpoint of survival, utilizing national registry data. Methods: We queried the United Network for Organ Sharing (UNOS) data registry for all heart transplants from 1987 to 2012. We restricted our analysis to adult (≥18 yr) recipients performed from 2001-2011 (to allow for the potential for a minimum of 12 months post-transplant follow-up) who received either: no antibody based induction (NONE) or the contemporary agents (INDUCED) of either: basiliximab/daclizumab (IL-2Rab), alemtuzumab, or ATG/ALG/thymoglobulin. Kaplan-Meier estimates of the survival function as well as Cox proportional hazards models were utilized. Results: Of the 17 857 heart transplants that met the inclusion criteria, there were 4635 (26%) reported deaths during the follow-up period. There were 8216 (46%) patients who were INDUCED. Of the INDUCED agents, 55% were IL-2Rab, 4% alemtuzumab, and 40% ALG/ATG/thymoglobulin. Donor and recipient characteristics were evaluated. Overall, being INDUCED did not significantly affect survival in univariable (p = 0.522) and multivariable (p = 0.130) Cox models as well as a propensity score adjusted model (p = 0.733). Among those induced, ATG/ALG/thymoglobulin appeared to have superior survival as compared with IL-2Rab (log-rank p = 0.007, univariable hazard ratio [HR] = 0.886; 95% CI: 0.811-0.968; p = 0.522). However, in a multivariable Cox model that adjusted for recipient age, VAD, BMI, steroid use, CMV match, and ischemic time, the hazard ratio for ALG/ATG/thymoglobulin vs. IL-2Rab was no longer statistically significant (HR = 0.948; 95% CI: 0.850-1.058; p = 0.341). Conclusion: In a contemporary analysis of heart transplant recipients, an overall analysis of induction agents does not appear to impact survival, as compared to no induction immunosuppression. While ALG/ATG/thymoglobulin appeared to have a beneficial effect on survival compared to IL-2Rab in the univariable model, this difference was no longer statistically significant once we adjusted for clinically relevant covariates.

UR - http://www.scopus.com/inward/record.url?scp=84920947798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920947798&partnerID=8YFLogxK

U2 - 10.1111/ctr.12469

DO - 10.1111/ctr.12469

M3 - Article

VL - 29

SP - 9

EP - 17

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1

ER -